Bayer Reaches $7.25 Billion Settlement Over Roundup Cancer Claims

The settlement aims to resolve thousands of lawsuits alleging Bayer failed to warn about Roundup's cancer risks.

Published on Feb. 21, 2026

Got story updates? Submit your updates here. ›

Agrochemical maker Bayer and attorneys for cancer patients announced a proposed $7.25 billion settlement to resolve thousands of U.S. lawsuits alleging the company failed to warn people that its popular weedkiller Roundup could cause cancer. The settlement comes as the Supreme Court prepares to hear arguments on Bayer's assertion that the EPA's approval of Roundup without a cancer warning should invalidate state court claims.

Why it matters

The proposed settlement would eliminate some of the risk from an eventual Supreme Court ruling on the EPA's role in approving Roundup's labeling. It would assure patients of receiving settlement money even if the Supreme Court rules in Bayer's favor, while also protecting Bayer from potentially larger costs if the high court rules against it.

The details

About 200,000 Roundup-related claims have been made against Bayer. The newly proposed nationwide settlement is designed to address most of the remaining lawsuits, as well as any additional cases brought in the coming years by people exposed to Roundup before the settlement. Settlement payouts to the sick would vary depending on factors like how they used Roundup and the severity of their non-Hodgkin lymphoma.

  • The proposed settlement was filed in St. Louis Circuit Court in Missouri on February 18, 2026.
  • The Supreme Court is preparing to hear arguments in April 2026 on Bayer's assertion that the EPA's approval of Roundup without a cancer warning should invalidate state court claims.

The players

Bayer

An agrochemical maker that acquired Roundup maker Monsanto in 2018. Bayer disputes the assertion that Roundup's key ingredient, glyphosate, can cause non-Hodgkin lymphoma.

Bill Anderson

Bayer's CEO, who stated that the settlement gives the company a 'road to closure' on the 'litigation uncertainty' that has plagued it for years.

Christopher Seeger

An attorney who would represent current claimants under the proposed settlement, stating that 'no settlement can erase a diagnosis, but this agreement is designed to ensure that both today's and tomorrow's patients have access to meaningful compensation.'

Matt Clement

An attorney who represents about 280 Roundup plaintiffs and said he was surprised by the proposed settlement, expecting that a lot of his clients will opt out because the proposed payouts 'are exceedingly too small.'

Got photos? Submit your photos here. ›

What they’re saying

“Litigation uncertainly has plagued the company for years, and this settlement gives the company a road to closure.”

— Bill Anderson, CEO, Bayer (Fortune)

“No settlement can erase a diagnosis, but this agreement is designed to ensure that both today's and tomorrow's patients have access to meaningful compensation.”

— Christopher Seeger, Attorney (Fortune)

“The proposed payouts 'are exceedingly too small.'”

— Matt Clement, Attorney (Fortune)

What’s next

The proposed settlement still needs the court's approval before it can be finalized.

The takeaway

This settlement represents a major development in the long-running legal battle over Roundup's alleged cancer risks, as Bayer seeks to resolve thousands of lawsuits and limit its exposure to potentially larger costs from future court rulings.